AI Article Synopsis

  • Haploidentical HSCT is a viable treatment for pediatric patients, especially in regions without bone marrow registries, with a study involving 20 patients from 2017 to 2022.
  • Most patients (70%) had malignant conditions, and complications included a significant incidence of graft-versus-host disease (GVHD), infections, and graft failures.
  • The overall survival rate was 40%, with challenges in managing GVHD and infections, particularly in benign diseases, indicating mixed outcomes compared to similar treatments in low-middle-income countries.

Article Abstract

Background: Haploidentical hematopoietic stem cell transplant (HSCT) is a curative treatment especially for countries where bone marrow registries are nonexistent. We present our experience with haploidentical HSCT in pediatric patients.

Methods: Retrospective data collected and analyzed for patients ≤18 years, from January 2017 to December 2022.

Results: The cohort consisted of 20 patients with median age at transplant of 61.5 (IQR: 124) months. Fourteen (70%) were malignant and 6 (30%) were benign diseases. Donors were father in majority (9/20; 45%). Stem cell source was peripheral blood 8, marrow 8, and combined 4. c-specific antibodies were positive in 6 (30%). Median CD34 cell dose infused: 9.35 × 10/kg. Median engraftment time: 15 (IQR: 17) days. Acute and chronic graft-versus-host disease (GVHD) occurred in 12/20 (60%) and 5/20 (25%), respectively. Complications included infection/sepsis (14/20; 70%), cytomegalovirus reactivation (14/20; 70%), sinusoidal obstruction syndrome (1/20; 5%), primary graft failure (PGF) (6/20; 30%), and secondary graft failure (4/20; 20%). PGF was more common in benign conditions (p = 0.003) and less prevalent in cases with aGVHD (p = 0.007). aGVHD was more common in malignant conditions (p = 0.007). Overall survival (OS), relapse-free survival (RFS), and treatment-related mortality (TRM) were 40%, 50%, and 35%, respectively. Median time of survival and relapse were 8 (IQR: 15) and 9 (IQR: 13) months, respectively.

Conclusion: OS was comparable to that of other low-middle-income countries. GVHD was a major challenge, along with sepsis and CMV infection. Half of the leukemias relapsed. Graft failure was a major concern in nonmalignant diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1111/petr.14842DOI Listing

Publication Analysis

Top Keywords

stem cell
12
graft failure
12
14/20 70%
8
initiation haploidentical
4
haploidentical stem
4
cell
4
cell transplantation
4
transplantation post-transplant
4
post-transplant cyclophosphamide
4
cyclophosphamide children
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!